Ascletis Pharma Selects ASC35 as Once-Monthly GLP-...
Category : Clinical Trial Update 13 October 2025Ascletis Pharma Inc. (HKEX: 1672) has unveiled ASC35, a next-generation GLP-1/GIP dual peptide agoni...
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
Ascletis Pharma Inc. (HKEX: 1672) has unveiled ASC35, a next-generation GLP-1/GIP dual peptide agoni...
Cidara Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy designation for CD3...
Dr Reddy’s Laboratories and Zydus Lifesciences are recalling products in the United States due...
Emalex Biosciences today announced that the U.S. Food and Drug Administration (FDA) has authorized t...
Jubilant Pharmova’s contract manufacturing arm, Jubilant HollisterStier (JHS), has launched it...